Drug Trial Radar · NCT02054130
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
Last checked: Nov 20, 2026Latest source record: Dec 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
584
Actual
Start
Dec 13, 2013
Primary completion
Dec 12, 2016
Study completion Mar 1, 2017
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Amgen
- First posted
- Feb 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
Conditions
- Asthma
Interventions
PlaceboDrug
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
MEDI9929 70 mgDrug
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
MEDI9929 210 mgDrug
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
MEDI9929 280 mgDrug
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Asthma Exacerbation Rate (AER) Through Week 52Time frame: Week 0 (Day 1) up to Week 52
Locations
107 sites in 12 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Miami, Florida
Research Site
Oviedo, Florida
Research Site
Savannah, Georgia
Research Site
Peoria, Illinois
Research Site
Baltimore, Maryland
Research Site
Rochester, Minnesota
Research Site
New York, New York
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Charlotte, North Carolina
Research Site
Dublin, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Rock Hill, South Carolina
Research Site
Spartanburg, South Carolina
Research Site
Houston, Texas
Research Site
Richmond, Virginia
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Velingrad, Bulgaria
Research Site
Brandýs nad Labem, Czechia
Research Site
Hradec Králové, Czechia
Research Site
Mladá Boleslav, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Strakonice, Czechia
Research Site
Balassagyarmat, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Csorna, Hungary
Research Site
Debrecen, Hungary
Research Site
Farkasgyepü, Hungary
Research Site
Gödöllő, Hungary
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.